Skip to main content

An integrated high-throughput human cell and Drosophila screening platform for the expedited discovery of anti-ageing compounds

Project description

Cell-based anti-ageing drug assessment platform

Population ageing together with age-related diseases make ageing research increasingly important. Previously, the project team developed the CellAge epigenetic clock, which is based on DNA methylation and can accurately detect subtle ageing changes in human primary cells in vitro after a short-term anti-ageing drug treatment using rapamycin and trametinib. The EU-funded AgePhagy project is now connecting the CellAge clock to their autophagy drug library to test the commercial viability of this anti-ageing drug assessment platform. To further validate the clock as a robust human ageing biomarker, the team will combine its outputs with in vivo longevity assays in Drosophila. The final outcome will be an innovative accelerated discovery platform for anti-ageing drugs.

Host institution

UNIVERSITY COLLEGE LONDON
Net EU contribution
€ 149 872,00
Address
Gower Street
WC1E 6BT London
United Kingdom

See on map

Region
London Inner London — West Camden and City of London
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00

Beneficiaries (1)

UNIVERSITY COLLEGE LONDON
United Kingdom
Net EU contribution
€ 149 872,00
Address
Gower Street
WC1E 6BT London

See on map

Region
London Inner London — West Camden and City of London
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00